PB1994: REAL WORLD DATA OF PATIENTS WITH MULTIPLE MYELOMA WITHOUT ACCESS A NOVEL AGENT IN FIRST LINE THERAPY IN PUBLIC HEALTH HOSPITAL IN MEXICO

Abstract

Background: Real World data of patients with Multiple Myeloma without access a novel agent in first line therapy in public Health hospital in Mexico Aims: To expose the 5-year OS and PFS of patients with multiple myeloma who did not use Bortezomib as first line therapy and to compare its use after first line. Methods: Observational, longitudinal and retrospective study. Measures of central tendency, Kaplan-Meier curves with Log-Rank as well as Cox regression were performed for survival analysis, with HR report, ranges were obtained considering significant a value of p <0.05 with 95% CI. 0.1 amplitude with 5% error Results: 265 patients, 126 (47.5%) male and 139 (52.5%) female, with a median age of 62 years (34-90). The 5-year OS was 47%. In PFS 55% at 1 year and 9% at 5 years. In comparison OS of subsequent line with Bortezomib versus absence, OS of 59% was reported in the Bortezomib arm versus 43% with HR of 1.819 (95% CI 1.235-2.677) with a P value of P=0.002. Summary/Conclusion: The absence of proteosome inhibitor as first line negatively impacts OS and PFS; its use even as subsequent line therapy may improve prognosis